tiprankstipranks
Astellas Pharma Withdraws EU Application for Key Drug
Company Announcements

Astellas Pharma Withdraws EU Application for Key Drug

Astellas Pharma (JP:4503) has released an update.

Don't Miss Our Christmas Offers:

Astellas Pharma has withdrawn its marketing application for avacincaptad pegol, a treatment for geographic atrophy linked to age-related macular degeneration, from the European Medicines Agency. Despite positive results in the U.S., the company cites interactions with the EMA as the reason for this decision, while remaining optimistic about the drug’s clinical benefits and committed to global regulatory engagement.

For further insights into JP:4503 stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Japan Auto-Generated NewsdeskAstellas Faces FDA Setback on IZERVAY Application
TipRanks Japan Auto-Generated NewsdeskAstellas Pharma Faces Currency Losses in FY2024
Austin AngeloALPMF Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App